Home > Boards > US OTC > Miscellaneous >

Vitality Biopharma Inc. (VBIO)

VBIO RSS Feed
Add VBIO Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/30/2019 10:16:35 AM - Followers: 64 - Board type: Free - Posts Today: 0

 

 

Vitality Biopharma (“Vitality”) (OTCQB: VBIO) is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders. We are interested in drug approvals first and foremost, but our overarching mission is to improve the lives of patients afflicted with devastating neurological and inflammatory conditions, such as multiple sclerosis.  We aim to go beyond providing symptomatic relief to patients afflicted with these disorders, such as treatment of muscle spasticity in multiple sclerosis, and to instead identify combination treatments that treat the underlying cause of disease and hold the potential to help patients recover lost function.

Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, the prodrug may be approved rapidly through demonstrating similar bioavailability or bioequivalence, and at the same time a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid.  As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.

One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 30 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today.




Cannabosides – A New Class of Cannabinoid Pharmaceuticals

Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.

Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.

In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.


 

Cannabosides – A Novel Class of Cannabinoid Prodrugs
Novel cannabinoid glycoside compositions of matter have reliably lead to dramatic improvements in drug solubility and stability, as evidenced below.
Patents are pending for more than 20 novel cannabinoid glycoside prodrugs (including prodrug versions of of CBD, THC, CBDV, and more).
As federal restrictions on medical research in this field are beginning to relax, and as interest from the public continues to mount, there is a striking increase in the number of clinical trials being sponsored by academic investigators for use of cannabinoids to treat lucrative, large market disease indications.  Given our ability to rapidly create proprietary prodrug versions of each these cannabinoids, we stand to benefit from emerging data, and increasing recognition from the medical community of the potent pain relief and anti-inflammatory effects of cannabinoids.

Studies have shown that cannabinoids can be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects.  Specifically, cannabinoid drugs can be nearly 10 times as potent as opiates for pain relief, including morphine.  Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation.





 

Our compounds take advantage of a targeted-release mechanism where microbial enzymes present in the intestines will enable a very site-specific localized release of compounds including THC, CBD, and many of the other known cannabinoids. Because of this, we could provide targeted relief of inflammatory bowel diseases (IBD) such as Crohn’s disease or ulcerative colitis, simply by enabling larger doses of cannabinoids to be delivered.

click photo to view presentation

 

Through extensive research in the natural sweetener industry, we pioneered industrial-scale processes to modify stevia to make it taste better. This process is known as glycosylation, which involves adding additional glucose molecules to it, and it modifies both the taste and solubility of it. Over the last 10 years or so, it has become appreciated within the pharmaceutical industry that glycosylation could act to generate new natural product libraries with improved drug properties. This process for modifying natural products to make them more useful is often called glycorandomization, or glycodiversification.

Using the same technology, we’ve now been able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”, which are novel cannabinoid prodrug pharmaceuticals. As an example, one of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has potential therapeutic effects in a wide variety of serious neurological and inflammatory conditions. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as site-specific delivery that avoids or reduces psychoactivity, a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that could enable long-lasting, overnight relief.

Vitality has filed intellectual property applications including strong composition of matter claims for prodrugs of THC, CBD, and CBDV, creating proprietary prodrugs of every significant cannabinoid pharmaceutical available today.





Company News & Media
 

Press Releases

 
Sep 13, 2016 Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications Press Release
Sep 12, 2016 Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference Press Release
Aug 24, 2016 Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio Press Release
Aug 17, 2016 Vitality Biopharma Begins Trading Under New Stock Symbol "VBIO" Press Release
Jul 27, 2016 Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease Press Release
Jul 19, 2016 Vitality Biopharma Name Change and Corporate Actions Receive Shareholder Approval Press Release
Jun 1, 2016 Vitality Biopharma to Present at LD Micro and BIO Conferences Press Release
May 9, 2016 Launch of Vitality Biopharma for Cannabinoid Prodrug Pharmaceutical Development Press Release
Sep 3, 2015 Stevia First Corp. to Present at Rodman & Renshaw 17th Annual Global Investment Conference Press Release
Aug 25, 2015 Stevia First Corp. Launches Campaign to Divorce Sports World From Sugary Beverages Press Release
 

CEO Blog

What We Should Know About Opiates and Prescription Drug Abuse September 8, 2016
Magnifying the Therapeutic Effects of Medical Marijuana through Targeted Delivery August 9, 2016
Our Company Turns Towards Drug Development and Cannabinoid Pharmaceuticals July 19, 2016
 

In the News


 

 





 

Company Info

Vitality Biopharma, Inc.
1901 Avenue of the Stars
2nd Floor
Los Angeles, California
90067

Telephone: (530) 231-7800
Fax: (866) 293-0655
Email: info@vitality.bio

VBIO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#2300   It apparently allows broker dealers to more easily elkonig 09/30/19 10:16:34 AM
#2299   Looks like this "Expert Market" thingy discussed here: 236T568 09/05/19 02:04:58 PM
#2298   Listed as "Expert Market", not grey 236T568 09/05/19 01:47:56 PM
#2297   off grey market? otc.. wunder 08/28/19 01:27:34 PM
#2296   I think they just did. allDigitalGroup 07/17/19 08:27:40 AM
#2295   There should be a 10K coming out very superchg2 06/23/19 05:56:53 AM
#2294   Hopefully the new management will concentrate on one Plumberhouston 06/22/19 08:10:36 AM
#2293   The VBIO Board has terminated their arrangement with superchg2 06/21/19 11:33:10 PM
#2292   No account with TDA and not worth opening sublett 06/21/19 11:11:22 AM
#2291   TD Ameritrade superchg2 06/21/19 10:55:22 AM
#2290   It would appear that former CEO Robert Brooke superchg2 06/20/19 02:44:59 AM
#2289   There is no buying activity because there is sublett 06/18/19 10:34:56 PM
#2288   Doesn't look good, nor has it for quite deecon 06/18/19 06:38:01 PM
#2287   Thanks for the thoughts... Rich30 06/13/19 10:57:08 PM
#2286   The two departures were prompted by the SEC. superchg2 06/11/19 09:17:30 PM
#2285   New to this board, but certainly not new sublett 06/11/19 11:07:32 AM
#2284   lol...it’s a joke... Rich30 06/04/19 06:45:22 PM
#2283   What lights? beachlifeguy 06/03/19 01:14:02 PM
#2282   Last person please shut the lights on the Rich30 05/28/19 05:33:20 PM
#2281   is it all a big ??? or is Mandofellow 05/28/19 03:03:49 PM
#2280   You are correct. Hopefully someone willl hold Rich30 05/11/19 11:21:34 AM
#2279   The signs were there that VBIO was behaving 236T568 05/10/19 11:58:54 PM
#2278   Sure looks that way. CEO was supposed Rigamortis Raccoon 05/09/19 11:02:19 AM
#2277   Sadly, it looks like VBIO fading into oblivion...easy Rich30 05/08/19 11:18:10 AM
#2276   Avtar dhillon resigned Jdanger 2 04/30/19 12:25:23 AM
#2275   So you're saying this can't be bought with fung_derf 02/20/19 10:42:51 AM
#2274   There arent any bids/ask/quotes for VBIO as they elkonig 02/20/19 05:21:46 AM
#2270   Which means, there is a bid and there fung_derf 02/14/19 03:09:41 PM
#2269   Which means what? Rich30 02/14/19 02:22:13 PM
#2267   Traders taking this up and down like a yo-yo... Rich30 02/14/19 12:14:26 PM
#2266   company may be in best shape ever beachlifeguy 02/13/19 09:42:29 AM
#2265   something brewing...?...company may be in best shape ever...was Mandofellow 02/12/19 11:22:24 AM
#2264   SOME buying activity would be a good start. deecon 02/08/19 11:26:41 AM
#2263   I wish I could share your optimism... Rich30 02/07/19 01:24:38 PM
#2262   There are 9 million reasons for Vitality to Plumberhouston 02/07/19 07:00:43 AM
#2261   Always looking for some sign that VBIO might Rich30 02/06/19 05:15:34 PM
#2260   multiple form 4's Mandofellow 01/29/19 05:11:38 PM
#2259   T, Whats your take on the 8K? TIA beachlifeguy 01/25/19 11:44:56 AM
#2258   what does latest news say about the mystery...? Mandofellow 01/25/19 10:58:24 AM
#2257   New 8K Plumberhouston 01/24/19 09:13:09 AM
#2256   By the looks of it yes- $4,200 worth..... Pikeslayer 01/22/19 12:33:40 PM
#2255   did someone pay 6.0 instead of .6...?...oops Mandofellow 01/22/19 11:32:46 AM
#2254   Its been 2 and a half months since beachlifeguy 01/20/19 04:16:26 PM
#2253   Two of the investors joined the board. One Plumberhouston 01/20/19 11:28:23 AM
#2252   sounds like a standard line to me, maybe beachlifeguy 01/20/19 11:14:53 AM
#2251   T, You were dead right about this Company, beachlifeguy 01/20/19 11:12:22 AM
#2250   Here is a quote from one of the Plumberhouston 01/19/19 06:29:13 PM
#2249   The signs were there that VBIO was behaving 236T568 01/19/19 01:10:43 PM
#2248   there may be more long term share holders Mandofellow 01/18/19 03:40:27 PM
#2247   my guess is that the high priced offering 236T568 01/18/19 02:55:39 PM
PostSubject